Clinical Trial News Archive - August 2020
August 3, 2020
- RLF-100 (aviptadil) Clinical Trial Showed Rapid Recovery from Respiratory Failure and Inhibition of Coronavirus Replication in Human Lung Cells
- Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
August 4, 2020
August 5, 2020
- Novartis Announces NEJM Publication of Phase III ASCLEPIOS Trials Demonstrating Superior Efficacy of Ofatumumab in Patients with Relapsing Multiple Sclerosis
- Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
- Pfizer and BioNTech to Supply Canada with their BNT162 mRNA-Based Vaccine Candidate
- BioNTech and Fosun Pharma Announce Start of Clinical Trial of mRNA-based COVID-19 Vaccine Candidate in China
- Gilead Sciences Statement on State Attorneys General Letter on Remdesivir
August 6, 2020
- Novavax and Serum Institute of India Announce Development and Commercial Collaboration
- Gilead Sciences Update on Veklury® (Remdesivir) Manufacturing Network
- FDA Grants Inhaled Use IND for RLF-100 (aviptadil) to Treat Patients with Moderate and Severe COVID-19 Aiming to Prevent Progression to Respiratory Failure
- Levo Therapeutics Announces Top-line Results from Phase 3 CARE-PWS Study of LV-101 (Intranasal Carbetocin) for the Treatment of Prader-Willi Syndrome
August 7, 2020
- FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
- Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
August 10, 2020
August 11, 2020
August 12, 2020
August 14, 2020
August 17, 2020
- Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
- Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa
- CytoDyn Submits its Top-line Report from its Phase 2 COVID-19 Trial to the U.S. FDA and Requests Emergency Use Approval
August 18, 2020
August 19, 2020
- AstraZeneca Australia & New Zealand Response to the COVID-19 Pandemic
- New England Journal of Medicine Publishes Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
August 20, 2020
August 24, 2020
August 25, 2020
- Phase I Clinical Trial Initiated for AstraZeneca's Monoclonal Antibody Combination AZD7442 for the Prevention and Treatment of COVID-19
- CytoDyn Reaches Enrollment of 195 Patients in its Phase 3 Trial for COVID-19 Patients with Severe-to-Critical Symptoms
August 27, 2020
August 28, 2020
- Gilead’s Investigational Antiviral Veklury (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19
- Ridgeback Biotherapeutics LP Announces Initiation of Expanded Access Protocol for Ebola Treatment Ansuvimab
August 29, 2020
August 30, 2020
August 31, 2020
Clinical trial results archive
- 2025
- January, February, March, April
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.